Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Friday, November 22, 2019 · 502,945,690 Articles · 3+ Million Readers

The global cancer immunotherapy market size is likely to reach USD 126.9 billion by 2026

Cancer Immunotherapy Market Analysis Report By Product (Oncolytic Viral Therapies & Cancer Vaccines, Monoclonal Antibodies, Immunomodulators), By Cancer Type (Breast, Lung), and Segment Forecasts, 2019 - 2026

/EIN News/ -- New York, Oct. 30, 2019 (GLOBE NEWSWIRE) -- announces the release of the report "Cancer Immunotherapy Market Analysis Report By Product, By Cancer Type And Segment Forecasts, 2019 - 2026" -

The global cancer immunotherapy market size is likely to reach USD 126.9 billion by 2026, exhibiting a CAGR of 9.6% during the forecast period. Increasing patient pool and higher mortality rate are augmenting the need for cancer immunotherapy globally. Furthermore, increasing number of approvals for new immunotherapeutic drugs is driving the global market.

Cancer immunotherapy has emerged as a new avenue for revenue generation for pharmaceutical companies.In addition, adverse effects, such as recurrence of cancer and organ failure, associated with conventional chemotherapies and rising demand for technologically advanced healthcare solutions are boosting the demand for immunotherapies.

Moreover, introduction of newer drug classes, such as target receptors for multiple myeloma and checkpoint inhibitors, is poised to make way for advanced therapeutics in the market.

Introduction of new molecules has been proving to be beneficial for patients who are not responding to chemotherapy. Several new immunotherapeutic options, such as immunomodulators and CAR-T cell therapy, are in the pipeline and are being tested for their ability to provide better cancer treatment.

Monoclonal antibodies are the most widely used immunotherapeutic drugs globally.Development of monoclonal antibodies as effective immunotherapeutic options started after the approval of Blincyto (blinatumomab) by Amgen, a bispecific antibody that targets B-cell lymphoblastic leukemia.

Increasing R&D pertaining to the use of monoclonal bodies as naked antigen binding antibodies, conjugated, and bispecific antibodies is resulting in discovery of new therapeutic options for cancer treatment.

Further key findings from the report suggest:
• Majority of immunotherapy drugs are being used in treatment of cancer of lung, breast, and prostate
• Monoclonal antibodies emerged as the largest segment because of increasing regulatory approvals and higher efficacy
• Lung cancer accounted for the largest share in 2018 and will continue to dominate the market through 2025
• North America was the leading revenue contributor in the market in 2018. Rising incidence of cancer and increasing demand for novel technologies are facilitating the dominance of the region during the forecast period
• Europe is projected to witness rapid growth during the forecast period owing to rapid adoption of advanced cancer therapeutics for effective treatment
• Some of the key players are Amgen, Inc.; AstraZeneca; F. Hoffmann La Roche Ltd.; Bayer AG; Bristol-Myers Squibb Company; Eli Lilly and Company; Merck and Co., Inc.; Novartis AG; and Pfizer, Inc.
Read the full report:

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.


                    US: (339)-368-6001
                    Intl: +1 339-368-6001
Powered by EIN News
Distribution channels: Media, Advertising & PR

EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release